{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HAE+With+Normal+C1+Esterase+Inhibitor", "query": { "condition": "HAE With Normal C1 Esterase Inhibitor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HAE+With+Normal+C1+Esterase+Inhibitor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T04:29:44.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06343779", "title": "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "C1 Esterase Inhibitor [C1-INH] Deficiency", "C1 Esterase Inhibitor Deficiency", "C1 Esterase Inhibitor, Deficiency of", "C1 Inhibitor Deficiency", "Hereditary Angioedema - Type 3", "Hereditary Angioedema Type III" ], "interventions": [ { "name": "Deucrictibant, Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 134, "start_date": "2024-02-26", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343779" }, { "nct_id": "NCT05396105", "title": "Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "Hereditary Angioedema - Type 3", "C1 Esterase Inhibitor [C1-INH] Deficiency", "C1 Esterase Inhibitor Deficiency", "C1 Esterase Inhibitor, Deficiency of", "C1 Inhibitor Deficiency", "Hereditary Angioedema Type III", "Hereditary Angioedema (HAE)", "Hereditary Angioedema Type I and II", "HAE With Normal C1 Esterase Inhibitor" ], "interventions": [ { "name": "deucrictibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 150, "start_date": "2022-12-28", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05396105" }, { "nct_id": "NCT00097695", "title": "Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Angioedema" ], "interventions": [ { "name": "Icatibant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2004-12-28", "completion_date": "2006-07-17", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097695" }, { "nct_id": "NCT00292981", "title": "C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "C1 Esterase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 57, "start_date": "2005-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2015-05-07", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 13, "location_summary": "Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more", "locations": [ { "city": "Weston", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00292981" }, { "nct_id": "NCT05047185", "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "C1 Esterase Inhibitor Deficiency", "C1 Inhibitor Deficiency" ], "interventions": [ { "name": "Deucrictibant low dose", "type": "DRUG" }, { "name": "Deucrictibant high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 34, "start_date": "2022-04-19", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047185" }, { "nct_id": "NCT05121376", "title": "A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hereditary Angioedema", "HAE" ], "interventions": [ { "name": "Dose 1 of BMN 331", "type": "GENETIC" }, { "name": "Dose 2 of BMN 331", "type": "GENETIC" }, { "name": "Dose 3 of BMN 331", "type": "GENETIC" }, { "name": "Dose 4 of BMN 331", "type": "GENETIC" }, { "name": "Dose 5 of BMN 331", "type": "GENETIC" }, { "name": "Dose 6 of BMN 331", "type": "GENETIC" }, { "name": "Dose 7 of BMN 331", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2022-02-15", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121376" }, { "nct_id": "NCT02052141", "title": "Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "CINRYZE 500", "type": "BIOLOGICAL" }, { "name": "CINRYZE 1000", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 12, "start_date": "2014-03-20", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 3, "location_summary": "Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052141" }, { "nct_id": "NCT02584959", "title": "Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "C1 esterase inhibitor [human] liquid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2015-11-01", "completion_date": "2017-07-24", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584959" }, { "nct_id": "NCT06690047", "title": "Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Ruconest", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bernstein Clinical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 5, "start_date": "2018-08-14", "completion_date": "2022-04-28", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Cincinnati, Ohio", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06690047" }, { "nct_id": "NCT04583007", "title": "Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Hereditary Angioedema (HAE)", "Angioedema" ], "interventions": [ { "name": "Lanadelumab 150 mg", "type": "DRUG" }, { "name": "Lanadelumab 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-10-01T04:29:44.423Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Chevy Chase", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583007" } ] }